DFX Intelligence

Data Factory

Private equityFirmbuyoutlower middle market

Aisling Capital Management LP

Private Equity

New York, NY

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:93455128-dac5-4a08-8697-812abd6bded0

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 6:23 PM UTC and rebuilt at most every 15 minutes.

Relationships: 151
Dated events: 18
On other graphs: 2
Observed: Sep 13, 2026 to Sep 16, 2026
33 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Independent Sponsorsidentity

Aisling Capital Management LP

Capital provider to sponsors · shared crd

RIA / Wealth Managementidentity

AISLING CAPITAL MANAGEMENT LP

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 2
PE funds: 2
Vintages: 2020 to 2020
PE GAV, 2024 filing: $511Mgross asset value on Form ADV; never dry powder
Regulatory AUM: $516M
Investments: 119
Active investments: 114
Size band: LOWER MIDDLE MARKETderivedproxy: $0.51bn Private Equity Fund GAV on the Form ADV filed 2024-03-28
Stated sectors: technology,life_sciences,healthcare
Latest ADV filing: Mar 28, 2024
Employees (ADV): 12
Website: aislingcapital.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV	LPs
Aisling Capital V, LP	2020	Mature	Private Equity Fund	n/a	$193M	0
Aisling Capital IV, LP	n/a	Unknown	Private Equity Fund	n/a	$317M	1

Investments

Company	State	Role	Control	Invested	Exited	Status
Biortus	n/a	Add on	control	Oct 28, 2025	n/a	active
Gondolabio	n/a	unknown	unknown	Jan 1, 2025	n/a	active
Scholar Rock	n/a	unknown	unknown	Jan 1, 2025	n/a	active
UroGen Pharma	n/a	unknown	unknown	Jan 1, 2025	n/a	active
BridgeBio Oncology Therapeutics	n/a	unknown	unknown	Jan 1, 2024	n/a	active
Calcimedica	n/a	unknown	unknown	Jan 1, 2024	n/a	active
Mindful Health Solutions	n/a	unknown	unknown	Jan 1, 2024	n/a	active
Bicara Therapeutics	n/a	unknown	unknown	Jan 1, 2023	n/a	active
Compass Pathways	n/a	unknown	unknown	Jan 1, 2023	n/a	active
Spyre Therapeutics	n/a	unknown	unknown	Jan 1, 2023	n/a	active
Commercial API Manufacturing Facility	n/a	Add on	control	May 24, 2022	n/a	active
Aesica Pharmaceuticals Limited	n/a	Add on	control	Jan 10, 2022	n/a	active
Dren Bio	n/a	unknown	unknown	Jan 1, 2022	n/a	active
Forge Biologics	n/a	unknown	unknown	Jan 1, 2022	n/a	active
Antios Therapeutics	n/a	unknown	unknown	Jan 1, 2021	n/a	active
Garuda Therapeutics, Inc.	n/a	unknown	unknown	Jan 1, 2021	n/a	active
Treeline Biosciences	n/a	unknown	unknown	Jan 1, 2021	n/a	active
Wugen	n/a	unknown	unknown	Jan 1, 2021	n/a	active
Biomea Fusion, Inc.	n/a	unknown	unknown	Jan 1, 2020	n/a	active
Monte Rosa Therapeutics, Inc.	n/a	unknown	unknown	Jan 1, 2020	n/a	active
OnKure Therapeutics	n/a	unknown	unknown	Jan 1, 2020	n/a	active
Spruce Biosciences, Inc.	CA	unknown	unknown	Jan 1, 2020	n/a	active
Syndax Pharmaceuticals, Inc.	n/a	unknown	unknown	Jan 1, 2020	n/a	active
Talaris Therapeutics	n/a	unknown	unknown	Jan 1, 2020	n/a	active
Elevation Oncology, Inc.	n/a	unknown	unknown	Jan 1, 2019	n/a	active
MKG LLC	n/a	unknown	unknown	Jan 1, 2019	n/a	active
Nuvation Bio	n/a	unknown	unknown	Jan 1, 2019	n/a	exited
Poseida Therapeutics, Inc.	n/a	unknown	unknown	Jan 1, 2019	n/a	active
Aeglea BioTherapeutics, Inc.	n/a	unknown	unknown	Jan 1, 2018	n/a	active
Armo Biosciences	n/a	unknown	unknown	Jan 1, 2018	n/a	active

LP commitments

Limited partner	Fund	Commitment	Committed	Vintage
Pennsylvania Public School Employees' Retirement System	n/a	$50.0M	n/a	2005
Pennsylvania Public School Employees' Retirement System	n/a	$50.0M	n/a	2008
Pennsylvania Public School Employees' Retirement System	Aisling Capital IV, LP	$100M	n/a	2015
New York State Common Retirement Fund	n/a	$35.0M	n/a	2005
New York State Common Retirement Fund	n/a	$45.0M	n/a	2008
New York State Common Retirement Fund	n/a	$45.0M	n/a	n/a

Relationships

showing 80 of 151

Invested in (69)

→ NanoTek, LLCCompanyAdd on
Aug 7, 2007 to presentfactNews and newswire
→ Advion BioSystemsCompanyplatform
factNews and newswire
→ Advion, Inc.Companyplatform
factNews and newswire
→ Assets of its BioSystems Manufacturing PartnerCompanyAdd on
Mar 12, 2008 to presentfactNews and newswire
→ Assets of its BioSystems Manufacturing PartnerCompanyAdd on
Mar 12, 2008 to presentfactNews and newswire
→ New API 5000CompanyAdd on
Jul 1, 2008 to presentfactNews and newswire
→ Aesica Pharmaceuticals LimitedCompanyAdd on
Jan 10, 2022 to presentfactNews and newswire
→ Pharmaron Beijing Co.Companyplatform
factNews and newswire
→ Commercial API Manufacturing FacilityCompanyAdd on
May 24, 2022 to presentfactNews and newswire
→ Pharmaron, Inc.Companyplatform
factNews and newswire
→ BiortusCompanyAdd on
Oct 28, 2025 to presentfactNews and newswire
→ AVANZA Laboratories, LLCCompanyunknown
Jan 1, 2009 to presentfactThe subject's own site
→ AVROBIO, Inc.Companyunknown
Jan 1, 2018 to presentfactThe subject's own site
→ Axcan Pharma, Inc.Companyunknown
Jan 1, 2000 to presentfactThe subject's own site
→ Barrier Therapeutics, Inc.Companyunknown
Jan 1, 2002 to presentfactThe subject's own site
→ Bicara TherapeuticsCompanyunknown
Jan 1, 2023 to presentfactThe subject's own site
→ Bioenvision, Inc.Companyunknown
Jan 1, 2002 to presentfactThe subject's own site
→ Biohaven Pharmaceuticals Ltd.Companyunknown
Jan 1, 2016 to presentfactThe subject's own site
→ Biomea Fusion, Inc.Companyunknown
Jan 1, 2020 to presentfactThe subject's own site
→ BridgeBio Pharma LLCCompanyunknown
Jan 1, 2017 to presentfactThe subject's own site
→ BridgeBio Oncology TherapeuticsCompanyunknown
Jan 1, 2024 to presentfactThe subject's own site
→ CalcimedicaCompanyunknown
Jan 1, 2024 to presentfactThe subject's own site
→ Cardiokine, Inc.Companyunknown
Jan 1, 2004 to presentfactThe subject's own site
→ CatalentCompanyunknown
Jan 1, 2007 to presentfactThe subject's own site
→ Cempra, Inc.Companyunknown
Jan 1, 2006 to presentfactThe subject's own site
→ ChimerixCompanyunknown
Jan 1, 2013 to presentfactThe subject's own site
→ Cidara Therapeutics, Inc.Companyunknown
Jan 1, 2008 to presentfactThe subject's own site
→ Clovis OncologyCompanyunknown
Jan 1, 2011 to presentfactThe subject's own site
→ GaldermaCompanyunknown
Jan 1, 2001 to presentfactThe subject's own site
→ Colorescience, Inc.Companyunknown
Jan 1, 2012 to presentfactThe subject's own site
and 39 more

Employs (11)

→ Robert John WenzelPersonChief Financial Officer and Chief Compliance Officer
factThe subject's own site
→ Wonpyo YunPersonPrincipal
factThe subject's own site
→ Steven Arnote ElmsPersonManaging Partner
factThe subject's own site
→ Andrew Newman SchiffPersonMd
factThe subject's own site
→ Sunny ReddyPersonPrincipal
factThe subject's own site
→ Carol ZikopoulosPersonHead of Human Resources and Compliance Manager
factThe subject's own site
→ Eric AguiarPersonMd
factThe subject's own site
→ Hannah WiederPersonController
factThe subject's own site
→ Scott BraunsteinPersonMd
factThe subject's own site
→ Aftab KheraniPersonMd
factThe subject's own site
→ Katie TanseyPersonVice President of Investor Relations and Marketing
factThe subject's own site

Dated events

2 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Dec 31, 2025
LP commitment disclosed
Pennsylvania Public School Employees' Retirement System reports Aisling Capital II L.P.: $50,000,000 committed, vintage 2005, net IRR 1.0%
Pennsylvania Public School Employees' Retirement System Plan disclosureobserved 6 days ago
$50.0M
Occurred
Dec 31, 2025
LP commitment disclosed
Pennsylvania Public School Employees' Retirement System reports Aisling Capital III, L.P.: $50,000,000 committed, vintage 2008, net IRR 26.5%
Pennsylvania Public School Employees' Retirement System Plan disclosureobserved 6 days ago
$50.0M
Occurred
Oct 28, 2025
Transaction announced
Pharmaron acquires Biortus in China
News and newswireobserved today
Occurred
Mar 31, 2025
LP commitment disclosed
New York State Common Retirement Fund reports Aisling Capital II, LP: $35,000,000 committed, vintage 2005
New York State Common Retirement Fund Plan disclosureobserved 6 days ago
$35.0M
Occurred
Mar 31, 2025
LP commitment disclosed
New York State Common Retirement Fund reports Aisling Capital III, LP: $45,000,000 committed, vintage 2008
New York State Common Retirement Fund Plan disclosureobserved 6 days ago
$45.0M
Occurred
May 24, 2022
Transaction announced
Pharmaron Acquires Commercial API Manufacturing Facility in the United States
News and newswireobserved today
Occurred
Jan 10, 2022
Transaction announced
Pharmaron Acquires Commercial API Manufacturing Facility in the United Kingdom from Recipharm
News and newswireobserved today
Occurred
Apr 21, 2017
Person left
Lloyd Eric Appel (Chief Financial Officer / Treasurer / Chief Compliance Officer) no longer on Schedule A of Aisling Capital Management LP
Form ADVobserved 6 days ago
Occurred
Aug 31, 2015
Adviser first adv filing
Aisling Capital Management LP first filed Form ADV in the extract (IA)
Form ADVobserved 6 days ago
Occurred
Jun 30, 2015
Exit
Advion Acquired by Beijing Bohui Innovation Technology, Inc.
Advion, Inc.News and newswireobserved today
Occurred
Jun 30, 2015
Transaction announced
Advion Acquired by Beijing Bohui Innovation Technology, Inc.
News and newswireobserved today
Occurred
Oct 1, 2008
LP commitment disclosed
New York State Common Retirement Fund reports Aisling Capital Partners III: $45,000,000 committed
New York State Common Retirement Fund Plan disclosureobserved 6 days ago
$45.0M
Occurred
Jul 1, 2008
Transaction announced
Advion Expands Its Bioanalytical Capabilities with Investment in New API 5000 and API 4000 Mass Spectrometers from Applied Biosystems/MDS Analytical Technologies
News and newswireobserved today
Occurred
Mar 12, 2008
Transaction announced
Advion Acquires the Assets of its BioSystems Manufacturing Partner
News and newswireobserved today
Occurred
Mar 12, 2008
Transaction announced
Advion Acquires the Assets of its BioSystems Manufacturing Partner
News and newswireobserved today
Occurred
Aug 7, 2007
Transaction announced
Advion BioSystems, Inc. Announces the Acquisition of NanoTek, LLC
News and newswireobserved today

Show 2 bookkeeping events

Occurred
Mar 30, 2020
Aisling Capital V, LP first reported on Form ADV by Aisling Capital Management LP (Private Equity Fund), GAV $64,146,336
Occurred
Aug 31, 2015
Aisling Capital IV, LP first reported on Form ADV by Aisling Capital Management LP (Private Equity Fund)

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Robert John Wenzel
Chief Financial Officer and Chief Compliance Officer · Revealable: 1 professional profile (firm website)
Wonpyo Yun
Principal · Revealable: 1 professional profile (firm website)
Steven Arnote Elms
Managing Partner · Revealable: 1 professional profile (firm website)
Andrew Newman Schiff
MD · Revealable: 1 professional profile (firm website)
Sunny Reddy
Principal · Revealable: 1 professional profile (firm website)
Carol Zikopoulos
Head of Human Resources and Compliance Manager · Revealable: 1 professional profile (firm website)
Eric Aguiar
MD · Revealable: 1 professional profile (firm website)
Hannah Wieder
Controller · Revealable: 1 professional profile (firm website)
Scott Braunstein
MD · Revealable: 1 professional profile (firm website)
Aftab Kherani
MD · Revealable: 1 professional profile (firm website)
Katie Tansey
Vice President of Investor Relations and Marketing · Revealable: 1 professional profile (firm website)

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:93455128-dac5-4a08-8697-812abd6bded0
First observed: Sep 13, 2026
Last observed: Sep 16, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Aisling Capital Management LP

Private Equity

New York, NY

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:93455128-dac5-4a08-8697-812abd6bded0

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 6:23 PM UTC and rebuilt at most every 15 minutes.

Fund

Vintage

Lifecycle

ADV type

Form D sold

GAV

LPs

Aisling Capital V, LP

2020

Mature

Private Equity Fund

n/a

$193M

Aisling Capital IV, LP

n/a

Unknown

Private Equity Fund

n/a

$317M

Company

State

Role

Control

Invested

Exited

Status

Biortus

n/a

Add on

control

Oct 28, 2025

n/a

active

Gondolabio

n/a

unknown

Jan 1, 2025

n/a

active

Scholar Rock

n/a

unknown

Jan 1, 2025

n/a

active

UroGen Pharma

n/a

unknown

Jan 1, 2025

n/a

active

BridgeBio Oncology Therapeutics

n/a

unknown

Jan 1, 2024

n/a

active

Calcimedica

n/a

unknown

Jan 1, 2024

n/a

active

Mindful Health Solutions

n/a

unknown

Jan 1, 2024

n/a

active

Bicara Therapeutics

n/a

unknown

Jan 1, 2023

n/a

active

Compass Pathways

n/a

unknown

Jan 1, 2023

n/a

active

Spyre Therapeutics

n/a

unknown

Jan 1, 2023

n/a

active

Commercial API Manufacturing Facility

n/a

Add on

control

May 24, 2022

n/a

active

Aesica Pharmaceuticals Limited

n/a

Add on

control

Jan 10, 2022

n/a

active

Dren Bio

n/a

unknown

Jan 1, 2022

n/a

active

Forge Biologics

n/a

unknown

Jan 1, 2022

n/a

active

Antios Therapeutics

n/a

unknown

Jan 1, 2021

n/a

active

Garuda Therapeutics, Inc.

n/a

unknown

Jan 1, 2021

n/a

active

Treeline Biosciences

n/a

unknown

Jan 1, 2021

n/a

active

Wugen

n/a

unknown

Jan 1, 2021

n/a

active

Biomea Fusion, Inc.

n/a

unknown

Jan 1, 2020

n/a

active

Monte Rosa Therapeutics, Inc.

n/a

unknown

Jan 1, 2020

n/a

active

OnKure Therapeutics

n/a

unknown

Jan 1, 2020

n/a

active

Spruce Biosciences, Inc.

unknown

Jan 1, 2020

n/a

active

Syndax Pharmaceuticals, Inc.

n/a

unknown

Jan 1, 2020

n/a

active

Talaris Therapeutics

n/a

unknown

Jan 1, 2020

n/a

active

Elevation Oncology, Inc.

n/a

unknown

Jan 1, 2019

n/a

active

MKG LLC

n/a

unknown

Jan 1, 2019

n/a

active

Nuvation Bio

n/a

unknown

Jan 1, 2019

n/a

exited

Poseida Therapeutics, Inc.

n/a

unknown

Jan 1, 2019

n/a

active

Aeglea BioTherapeutics, Inc.

n/a

unknown

Jan 1, 2018

n/a

active

Armo Biosciences

n/a

unknown

Jan 1, 2018

n/a

active

Limited partner

Fund

Commitment

Committed

Vintage

Pennsylvania Public School Employees' Retirement System

n/a

$50.0M

n/a

2005

Pennsylvania Public School Employees' Retirement System

n/a

$50.0M

n/a

2008

Pennsylvania Public School Employees' Retirement System

Aisling Capital IV, LP

$100M

n/a

2015

New York State Common Retirement Fund

n/a

$35.0M

n/a

2005

New York State Common Retirement Fund

n/a

$45.0M

n/a

2008

New York State Common Retirement Fund

n/a

$45.0M

n/a